U.S. Eli Lilly to buy cancer drugmaker Loxo Oncology for $8 billion

01/07/2019 3:06:00 PM (GMT)

U.S.-based pharmaceutical company Eli Lilly & Co. plans to acquire cancer drug developer Loxo Oncology Inc. in a deal valued at $8 billion.

Eli Lilly & Co. will pay Loxo Oncology $235 a share, representing a 68 percent premium.

The company said it will complete the transaction by the end of this first quarter.

In 2017, Eli Lilly booked $22.9 billion in revenue.

Eli Lilly & Co.

All success stories are prepared by Investsize editors which is selecting elite and remarkable information from press releases and anonymous news sources.There is no charge applied for any success stories which is published . Those published success stories are not investment advices and doesnt offer recommendations Alternate Text